CL2019002174A1 - Composición que comprende capecitabina de liberación inmediata y liberación prolongada. - Google Patents

Composición que comprende capecitabina de liberación inmediata y liberación prolongada.

Info

Publication number
CL2019002174A1
CL2019002174A1 CL2019002174A CL2019002174A CL2019002174A1 CL 2019002174 A1 CL2019002174 A1 CL 2019002174A1 CL 2019002174 A CL2019002174 A CL 2019002174A CL 2019002174 A CL2019002174 A CL 2019002174A CL 2019002174 A1 CL2019002174 A1 CL 2019002174A1
Authority
CL
Chile
Prior art keywords
release
composition
capecitabine
prolonged
immediate release
Prior art date
Application number
CL2019002174A
Other languages
English (en)
Inventor
Kashyap Gandhi
Piyush Patel
Manish Patel
Manish Chauhan
Ashish Sehgal
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of CL2019002174A1 publication Critical patent/CL2019002174A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA DE CAPECITABINA, EN DONDE DICHA COMPOSICIÓN COMPRENDE CAPECITABINA DE LIBERACIÓN INMEDIATA Y CAPECITABINA DE LIBERACIÓN PROLONGADA. ADEMÁS, LA PRESENTE INVENCIÓN DESCRIBE UN PROCEDIMIENTO PARA LA PREPARACIÓN DE DICHA COMPOSICIÓN.
CL2019002174A 2017-02-06 2019-08-02 Composición que comprende capecitabina de liberación inmediata y liberación prolongada. CL2019002174A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201721004194 2017-02-06

Publications (1)

Publication Number Publication Date
CL2019002174A1 true CL2019002174A1 (es) 2019-11-29

Family

ID=63040300

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019002174A CL2019002174A1 (es) 2017-02-06 2019-08-02 Composición que comprende capecitabina de liberación inmediata y liberación prolongada.

Country Status (13)

Country Link
US (1) US20190358253A1 (es)
EP (1) EP3576721A4 (es)
JP (1) JP2020514314A (es)
CN (1) CN110290779A (es)
AU (1) AU2018214291A1 (es)
BR (1) BR112019016028A2 (es)
CA (1) CA3051040A1 (es)
CL (1) CL2019002174A1 (es)
IL (1) IL268137A (es)
MX (1) MX2019009230A (es)
PH (1) PH12019501689A1 (es)
RU (1) RU2019126572A (es)
WO (1) WO2018142359A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122481A1 (en) * 1998-11-02 2007-05-31 Elan Corporation Plc Modified Release Compositions Comprising a Fluorocytidine Derivative for the Treatment of Cancer
DE112006000873T5 (de) * 2005-04-12 2008-03-06 Elan Pharma International Ltd. Zusammensetzungen mit modifizierter Freisetzung, umfassend ein Fluorcytidin-Derivate zur Behandlung von Krebs
CA2794513A1 (en) * 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
AU2016280148A1 (en) * 2015-06-13 2018-01-04 Intas Pharmaceuticals Ltd. Extended release Capecitabine capsules
CN104997744B (zh) * 2015-08-04 2018-01-23 青岛市中心医院 一种高稳定性卡培他滨片剂及其制备方法

Also Published As

Publication number Publication date
AU2018214291A1 (en) 2019-08-01
PH12019501689A1 (en) 2020-03-09
EP3576721A4 (en) 2020-07-22
MX2019009230A (es) 2019-09-10
RU2019126572A (ru) 2021-03-09
IL268137A (en) 2019-09-26
BR112019016028A2 (pt) 2020-03-31
CN110290779A (zh) 2019-09-27
CA3051040A1 (en) 2018-08-09
JP2020514314A (ja) 2020-05-21
US20190358253A1 (en) 2019-11-28
EP3576721A1 (en) 2019-12-11
WO2018142359A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
CL2023001909A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
DOP2019000040A (es) Compuestos de pirrolizina sustituidas y usos de los mismos
ECSP21072161A (es) Composiciones de liberación retardada de linaclotida
BR112018073384A2 (pt) polinucleotídeos moduladores
CL2016002772A1 (es) Composiciones de insulina de rápida acción
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
SV2018005643A (es) Composiciones de insulina de rapida accion
CL2015002891A1 (es) Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
BR112018003178A2 (pt) absorvente feminino com braçadeiras de barreira
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
SV2017005412A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2020001264A1 (es) Compuestos y métodos sintéticos para la preparación de retinodes específicos del receptor x retinoide.
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
BR112016028697A2 (pt) artigos que fornecem fragrâncias de longa duração
DOP2018000066A (es) Compuestos útiles para inhibir ror-gamma-t
AR104591A1 (es) Piroglutamato de vortioxetina
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
BR112017011168A2 (pt) medicamentos para retardar a doença de parkinson
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
BR112017012938A2 (pt) uso por via oral de uma composição e método para aprimorar a aparência da celulite
UY37572A (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer